Latest GlaxoSmithKline Stories
As Time published on April 30, a new study revealed that selective serotonin reuptake inhibitors (SSRIs), including Paxil, are linked to higher risk of complications after surgery. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Paxil side effects. San Diego, CA (PRWEB) May 24, 2013 AttorneyOne.com, a recognized authority on law, updated the...
NEW YORK, May 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D., Ph.D., to its Board of Directors. Dr. Almenoff has extensive experience in the pharmaceutical industry, working on early and late stage drug development. "We are delighted to have Dr. Almenoff join Ohr's Board," said Dr. Irach Taraporewala, CEO of Ohr...
Actos (pioglitazone) is a Type 2 diabetes drugs that was approved by the U.S. Food and Drug Administration (FDA) in 1999. Parker Waichman LLP has filed a lawsuit on behalf of a South Dakota man who took the drug, and alleges that it caused his bladder cancer; the case is one of thousands filed into the Actos multidistrict litigation, where Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee. New York, NY (PRWEB) May 20, 2013 Parker...
LONDON and SOUTH SAN FRANCISCO, Calif., May 10, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in...
New Non-Oral Triptans and Non-Triptan Products Will Provide Acute Treatment Alternatives for Oral Triptan Non-Responders, According to a New Report from Decision Resources BURLINGTON, Mass., May 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists and primary care physicians (PCPs) expect to more than double their use of Allergan's prophylactic migraine treatment...
Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder NORTH WALES, Pa. and MOUNTAIN VIEW, Calif., May 8, 2013 /PRNewswire/ -- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE...
ST. PAUL, Minn., May 7, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that it has been awarded two Honorable Mentions in the 2012 Award for Excellence from the Journal of Managed Care Pharmacy (JMCP). One study examined the impact of generic drug discount programs on levothyroxine (a drug to treat low thyroid) pharmacy claims data. A second study reviewed members' medication use following the implementation of a...
NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. (Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-a )(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-b ) The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's leading acid...
A UCLA-led study of adolescents receiving treatment for methamphetamine dependence has found that girls are more likely to continue using the drug during treatment than boys, suggesting that new approaches are needed for treating meth abuse among teen girls. Results from the study, conducted by the UCLA Center for Behavioral and Addiction Medicine and the community-based substance abuse treatment program Behavioral Health Services Inc., are published in the April edition of the Journal of...
RnRMarketResearch.com offers 2013 pharmaceutical market research reports for Denmark, Belgium, Austria, Cuba, Finland, Ireland & Norway DALLAS, April 29, 2013 /PRNewswire-iReach/ -- "The Pharmaceutical Market: Norway," "The Pharmaceutical Market: Austria," "The Pharmaceutical Market: Belgium," "The Pharmaceutical Market: Ireland," "The Pharmaceutical Market: Denmark," "The Pharmaceutical Market: Finland" and "The Pharmaceutical Market: Cuba" are new reports available at RnR Market...
